1069120-41-7

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 118785-97-0 cis-4-amino-cyclohexanecarboxylic acid hydrochloride 
• 62456-15-9 methyl (1s,4s)-4-aminocyclohexane-1-carboxylate 
• 124-63-0 methanesulfonyl chloride 
• 223131-01-9 tert-butyl ((cis)-4-(hydroxymethyl)cyclohexyl)carbamate 

Downstream Products

• 917022-17-4 tert-butyl (1s,4s)-4-(azidomethyl)cyclohexylcarbamate 
• 509142-53-4 tert-butyl ((cis)-4-((((benzyloxy)carbonyl)amino)methyl)cyclohexyl)carbamate 
• 509142-55-6 cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine

Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both Gi/o-bi

Indoleamine 2, 3-dioxygenase inhibitor and use thereof

The invention belongs to the technical field of medical technology and relates to a compound shown in the formula I and its pharmaceutically acceptable salt, isomer and prodrug. In the formula, R1, R2, R3, X, m, n and a ring A are defined in the specifica

Antitumor compounds based on a natural product consensus pharmacophore

We report the design and highly enantioselective synthesis of a potent analogue of the spliceosome inhibitor FR901464, based on a non-natural product scaffold. The design of this compound was facilitated by a pharmacophore hypothesis that assumed key interaction types that are common to FR901464 and an otherwise unrelated natural product (pladienolide). The synthesis allows for the preparation of numerous novel analogues. We present results on the in vitro activity for this compound against several tumor cell lines.